35
Views
26
CrossRef citations to date
0
Altmetric
Miscellaneous

Caspases: recent advances in small molecule inhibitors

Pages 1593-1603 | Published online: 25 Feb 2005

Bibliography

  • YUAN J, SHAHAM S, LEDOUX S, ELLIS HM, HORVITZ HR: The C. Degany cell death gene ced-3 encodes a protein similar to the mammalian interleukin-lfi converting enzyme. Cell (1993) 75:641–652.
  • ALNEMRI ES, LIVINGSTON DJ, NICHOLSON DW et al: Human ICE/ CED-3 protease nomenclature. Cell (1996) 87:171.
  • •Good review on targeting neuronal apoptosis.
  • BLACK RA, KRONHEIM SA, SLEATH: Activation of interleukin- 1 fi by a co- protease. FEBS Letts. (1989) 247:386–390.
  • KOSTURA MJ, TOCCI MJ, LIMJUCO G et al: Identification of a monocyte specific pre-interleukin-lp convertase activity. Proc. Natl. Acad. Li. USA (1989) 86:5227–5231.
  • KERR JFR, WYLLIE AH, CURRIE AR: Apoptosis: a basic biological phenomenon with wide ranging implications in tissue kinetics. Br. J. Cancer (1972) 26:239–257.
  • WOLF BB, GREEN DR: Suicidal tendencies: apoptotic cell death by caspase family proteases. j Biol. Chem. (1999) 274(29):20049–20052.
  • THORNBERRY NA: Caspases: key mediators of apoptosis. Chem. Biol. (1998) 5:R97–103.
  • HIROKAZU H, ATSUSHI T, SUSUMU K, SHINY, HIROFUMO S, TOSHIRO 0: Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. j Exp. Med. (1998) 187(4):587–600.
  • THORNBERRY NA, LAZEBNIK Y: Caspases: enemies within. Science (1998) 281:1312–1316.
  • GRUTTER MG: Caspases: key players inprogrammed cell death. Cum: Opin. Struct. Biol. (2000) 10:648–655.
  • THORNBERRY NA, RANO TA, PETERSON EP et al.: A combinatorial approach defines specificities of members of the caspase family and Granzyme B. Functional relationships established for key mediators of apoptosis. j Biol. Chem. (1997) 272:17907–17911.
  • TANO TA, TIMKEY T, PETERSON EP etal.: A combinatorial approach for determining protease specificities: application to interleukin-113 converting enzyme (ICE). Chem. Biol. (1997) 4:149–155.
  • BUDIHARDJO I, OLIVER H, LUTTER, LUO X, WANG X: Biochemical pathways of caspase activation during apoptosis. Ann. Rev Cell Dev. Biol. (1999) 15:269–290.
  • EARNSHAW WC, MARTINS LM, KAUFMANN SH: Mammalian caspases: structure, activation, substrates and functions during apoptosis. Ann. Rev Biochem. (1999) 68:383–424.
  • WALKER NE TALANIAN RV, BRADY KD et al.: Crystal structure of the cysteine protease interleukin-10 converting enzyme: a (p20/p10)2 homodimer. Cell (1994) 78:343–352.
  • WILSON KP, BLACK JA, THOMSON JA et al.: Structure and mechanism of interleukin-10 converting enzyme. Nature (1994) 370 270–275.
  • ROTUNDA J, NICHOLSON DW, FAZIL KM etal.: The three dimensional structure of apopain/CPP32, a key mediator of apoptosis. Nat. Struct. Biol. (1996) 3:619–625.
  • MITTL PR, DI MARCO S, KREBS JF et al.: Structure of recombinant human CPP32 in complex with the tetrapeptide acetyl-Asp-Val-Ala-Asp fluoromethyl ketone. j Biol. Chem. (1997) 272:6539–6547.
  • BLANCHARD H, DONEPUDI M, TSCHOPP M, KODANTAPANI L, WU JC, GRUTTER MG: Caspase-8 specificity probed at subsite S4: crystal structure of the caspase-8-Z-DEVD-CHO complex. I Md. Biol. (2000) 8:5031–5036.
  • NICHOLSON DW: Caspase structure, proteolytic substrates and function during apoptotic cell death. Cell Death and Differentiation (1999) 6:1028–1042.
  • STENNICKE HR, SALVESEN GS: Catalytic properties of the caspases. Cell Death and Differentiation (1999) 6:1054–1059.
  • GARCIA-CALVO M, PERTERSON EP, LEITING B, RUEL R, NICHOLSON DW, THORNBERRY NA: Inihibition of human caspases by peptide-based and macromolecular inhibitors. j Biol. Chem. (1998) 273:32608–32613.
  • HETTS SW: To die or not to die: an overview of apoptosis and its role in disease. J Am. Med. Assoc. (1998) 279(4):300–307.
  • LARNER AJ: Neuronal apoptosis as a therapeutic target in neurodegenerative disease. Expert Opin. Ther. Patents (2000) 10(10):1493–1518.
  • LOS M, WESSELBORG S, SCHULZE-OSTHOFF, K: The role of caspases in development, immunity and apoptotic signal transduction: lessons from knockout mice. 'mm1111_0, (1999) 10:629–239.
  • MCBRIDE CB, MCPHAIL LT, STEEVES JD: Emerging therapeutic targets in caspase-dependent disease. Emerg. Ther. Targets (1999) 3(3):391–411.
  • MARKS N, BERG MJ: Recent advances on neuronal caspases in development and neurodegeneration. Neurochem. Int. (1999) 34:195–220.
  • SASTRY PS, SUBBA RAO K: Apoptosis and the nervous system. I Neurochem. (2000) 74(1):1–20.
  • TALANIAN RV, BRADY KD, CRYNS VL: Caspases as targets for anti-inflammatory and anti-apoptotic drug discovery. I Med. Chem. (2000) 43(18):3351–3371.
  • ••Very good review article on targetingcaspases.
  • BRAUN JS, TUOMANEN El, CLEVELAND JL: Neuroprotection by caspase inhibitors. Expert Opin. Invest. Drugs (1999) 8(10):1599–1610.
  • SCHULZ JB, WELLER M, MM: Caspases as treatment targets in stroke and neurodegenerative diseases. Annals of Neurology (1999) 45:421–429.
  • KERR JFR, WYLLIE AH, CURRIE AR: death: the significance of apoptosis. Cytol. (1980) 68:251–306.
  • •Overview of apoptosis and its biological significance from the authors who first described the phenomenon.
  • THOMPSON CB: Apoptosis in the pathogenesis and treatment of disease. Science (1995) 267:1456–1462.
  • KIM TW, PETTINGELL WH, JUNG YK, KOVACS DM, TANZI RE: Alternative cleavage of Alzheimer-associated presenillins during apoptosis by a caspase 3 family protease. Science (1997) 277:373–376.
  • BARNES NY, LI L, YOSHIKAWA K et al.: Increased production of amyloid precursor protein provides a substrate for caspase 3 in dying motorneurons. j Neurosci. (1998) 18(15):5869–5880.
  • WALTER J, SCHINDZIELORZ A, GRUNBERG J, HAASS C: Phosphorylation of presenilin-2 regulates its cleavage by caspases and retards progression of apoptosis. Proc. Nati Acad. Sci. USA (1999) 964):1391–1396.
  • GERVAIS FG, XU D, ROBERTSON GS et al.: Involvement of caspases in proteolytic cleavage of Alzheimers amyloid-beta precursor protein and amyloidogenic A 13 peptide formation. Cell (1999) 97:395–406.
  • DODEL RC, DU YS, BALES KR et al.: Caspase 3-like proteases and 6-hydroxydopamine induced neuronal cell death. Ma. Brain Res. (1999) 64(1):141–148.
  • TAKAI N, NAKANISHI H, TANABE K etal: Involvement of caspase-like proteinases in apoptosis of neuronal Pc 1 2 cells and primary cultured microglia induced by 6-hydroxydopamine. I Neurosci. Res. (1998) 54(2):214–222.
  • PASINELLI P, BORCHELT DR, HOUSEWEART MK, CLEVELAND DW, BROWN RH: Caspase-1 is activated in neural cells and tissue with amyotrophic lateral sclerosis-associated mutations in copper-zinc superoxide dismutase. Proc. Natl. Acad. Sri. USA. (1998) 95(26)15763–15768.
  • SANCHEZ I, XU C-J, JUO P et al.: Caspase-8 is required for cell death induced by expanded polyglutamine repeats. Neuron (1999) 22:623–633.
  • PERUTZ MF: Glutamine repeats and neurodegenerative diseases: molecular aspects. Trends Biochem. Sri. (1999) 24(2):58–63.
  • FEUERSTEIN G, RUFFOLO RR, YUE T-: Apoptosis and congestive heart failure. Trends Cardiovasc. Med. (1997) 7(7):249–255.
  • NARULA J, PANDEY P, ARBUSTINI E etal.: Apoptosis in heart failure: release of cytochrome c from mitochondria and activation of caspase 3 in human cardiomyopathy. Proc. Nati Acad. Li. USA. (1999) 96:8144–8149.
  • KRAJEWSKI S, KRAJEWSKA M, ELLERBY LM et al.: Release of caspase-9 from mitochondria during neuronal apoptosis and cerebral ischemia. Proc. Nati Acad. Sri. USA. (1999) 96:5752–5757.
  • REED JC, PATERNOSTRO G: Postmitochondrial regulation of apoptosis during heart failure. Proc. Nati Acad. Li. USA. (1999) 96:7614–7616.
  • CURSIO R, GUGENHEIM J, RICCI JE et al.: A caspase inhibitor fully protects rats against lethal normothermic liver ischemia by inhibition of liver apoptosis. FASEB (1999) 13:253–261.
  • HIMI T, ISHIZAKI Y, MUROTA S: A caspase inhibitor blocks ischemia-induced delayed neuronal cell death in the gerbil. Eur. Neurosci. (1998) 10:777–781.
  • GHAYUR T, HAYS SJ, TALANIAN RV: Caspase 1 (ICE) and other caspases as drug discovery targets: Opportunities and progress. In: High Throughput Screening for Novel Ariti-billammatories. Kahn M (Ed.), Birkhauser Verlag Publishers, Basel, Switzerland (2000):35–48.
  • IWAMURA H: Recent advances in cytokine synthesis inhibitors. 'drugs (2000) 3(7):774–782.
  • SEKINE C, YAGITA H, KOBATA T et al.: Fas -mediated stimulation induces IL-8 secretion by rheumatoid arthritis synovicytes independent of CPP32-mediated apoptosis. Biochem. Biophys. Res. Comm. (1996) 228(1)14–20.
  • KOBAYASHI K, HATANO M, OTAKI M, OGASAWARA T, TOKUHISA T: Expression of a murine homologue of the inhibitor of apoptosis protein is related to cell proliferation. Proc. Natl. Acad. Sri. USA. (1999) 96(4):1457–1462.
  • LEE D, LONG SA, ADAMS JL et al: Potent and selective non-peptide inhibitors of caspases 3 and 7 inhibit apoptosis and maintain cell functionality. 1 Biol. Chem. (2000) 275(21):16007–16014.
  • ••First report of caspase 3/7 specific smallmolecule with supporting biological data.
  • LEE D, LONG SA, MURRAY JH et al.: Potent and selective non-peptide inhibitors of caspases 3 and if J Med. Chem. (2001) 44:2015–2026.
  • HOGLEN NC, HIRAKAWA BP, FISHER CD et al.: Characterization of the caspase inhibitor IDN-1965 in a model of apoptosis-associated liver injury. 1 Pharmacol. Exp. Therap. (2001)297:811–818.
  • GUNASEKERA SP, McCARTHY PJ, LONGLEY RE, POMPONI SA, AE: Secobatzellines A and B, two new enzyme inhibitors from a deep water Caribbean sponge of the genus Batzella. I. Nat. Prod. (1999) 62:1208–1211.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.